Survival in myeloma is clearly being prolonged,” says Mikhael. “Whereas historically, we saw a greater impact in younger ...

Mezigdomide (a CELMoD) combined with carfilzomib/dexamethasone met the phase 3 primary endpoint, delivering statistically ...

Refractory multiple myeloma means that your blood cancer isn’t responding to treatment. Your doctor may also refer to this as “progressive disease.” Hearing that your treatment isn’t slowing the ...

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...

Monoclonal gammopathies represent a broad differential diagnosis and require a thorough evaluation for clinical significance. Smoldering multiple myeloma is a clinical entity that does not require ...

Tumour reactive T cells identified through transcriptional profiling predict response to multiple myeloma immunotherapy and track treatment activity.